FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer

    NEXT STORY
    Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucoma
    PREV STORY
    Guardant Health Announces Pricing of Upsized Public Offering
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Panbela Announces Research Agreement with Johns Hopkins University School of Medicine

    author_avatar
    NASDAQ Market News

    XBiotech Announces On-Time Submission to the EMA

    AUSTIN, Texas, March 27, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that ...

    author_avatar
    NASDAQ Market News

    Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer

    Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination ...

    author_avatar
    NASDAQ Market News